SCHEMBL23042408

SCHEMBL23042408

N#Cc1nn(-c2cc(Cl)c(Oc3ccc4ncccc4c3)c(Cl)c2)c(=O)[nH]c1=O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
THRB P10828 18/20 0.52
THRA P10827 16/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C8 P10632 1/20 0.52
CYP3A4 P08684 1/20 0.44
PPARG P37231 1/20 0.44
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
OPRK1 P41145 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
UGT1A1 P22309 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
SLCO1B1 Q9Y6L6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30460718 0.87 THRB (0.52) THRBTHRACYP2C9CYP2C8NPC1
SCHEMBL25768561 0.87 THRB (0.52) THRBTHRACYP2C9CYP2C8NPC1
SCHEMBL23042578 0.86 THRA (0.54) THRBTHRACYP2C9CYP2C8NPC1
SCHEMBL25873840 0.85 THRB (0.53) THRBTHRACYP2C9CYP2C8NPC1
SCHEMBL29612524 0.85 THRB (0.53) THRBTHRACYP2C9CYP2C8NPC1
SCHEMBL31301017 0.84 THRB (0.50) THRBTHRACYP2C9CYP2C8NPC1
SCHEMBL25768562 0.84 THRB (0.50) THRBTHRACYP2C9CYP2C8NPC1
SCHEMBL23042363 0.84 THRB (0.52) THRBTHRACYP2C9CYP2C8NPC1
SCHEMBL25873870 0.84 THRA (0.55) THRBTHRACYP2C9CYP2C8NPC1
SCHEMBL30460687 0.83 THRB (0.53) THRBTHRACYP2C9CYP2C8NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528791-B2 Thyroid hormone receptor beta agonist compounds TERNS PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
US-20230226038-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS VIKING THERAPEUTICS, INC. 2023-07-20 US disclosed
US-20220281849-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS PHARMACEUTICALS, INC. 2022-09-08 US disclosed
EP-4017875-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns Pharmaceuticals, Inc. (US) 2022-06-29 EP disclosed
CN-114430743-A Thyroid hormone receptor beta agonist compounds 拓臻制药公司 2022-05-03 CN disclosed
WO-2021041237-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528791-B2 Thyroid hormone receptor beta agonist compounds THRB, THRA, TSHR THRB 1/4885THRA 2/4885CYP2C9 1737/4885
US-20220281849-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR THRB 1/4885THRA 2/4885CYP2C9 3768/4885
US-20230226038-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS FABP1, SLC10A1, LIPC THRB 19/4885THRA 25/4885CYP2C9 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.